Analyst Ratings For Axsome Therapeutics
Portfolio Pulse from Benzinga Insights
Analyst ratings for Axsome Therapeutics (NASDAQ:AXSM) show a diverse range of perspectives, with a notable shift towards more bullish sentiments in the last three months. The average 12-month price target for AXSM has increased to $130.3, reflecting a positive outlook on the company's future. Axsome Therapeutics, a clinical-stage biopharmaceutical company, has shown significant revenue growth of 193.5% as of December 31, 2023, outperforming its peers in the Health Care sector. However, challenges such as a net margin of -137.92% and a high debt-to-equity ratio of 0.98 indicate potential financial hurdles.
April 10, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has received increasingly bullish analyst ratings, with a rising average 12-month price target. The company's significant revenue growth contrasts with financial challenges like a high net margin loss and debt ratio.
The positive shift in analyst ratings and the increase in the average price target suggest a bullish outlook for AXSM in the short term. However, investors should be cautious due to the company's financial challenges, including a significant net margin loss and a high debt-to-equity ratio, which could impact its ability to sustain growth and manage debt effectively.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100